Biochem/physiol Actions
Studies have reported that TNP-470 can decrease intimal neovascularization in Apo-E deficient mice. TNP-470 can also prevent tumor growth in human breast and prostate cancer cell lines.
TNP-470 is a methionine aminopeptidase-2 (MetAP-2) inhibitor, selective for MetAP-2 over MetAP11. TNP-470 is an antiangiogenic.
Features and Benefits
This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
TNP-470 is a synthetic analogue of fumagillin. It is a natural product of Aspergillus fumigatus. TNP-470 serves as an angiogenesis inhibitor.
Other Notes
TNP-470 is hygroscopic.
Packaging
5, 25 mg in glass bottle
Preparation Note
TNP-470 is soluble in DMSO at a concentration that is greater than 15 mg/ml.
This product has met the following criteria: